M402 is a novel heparan sulfate mimetic that binds to multiple growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis. The use of heparins to treat venous thrombosis in cancer patients has generated numerous reports of antitumor activity; however, the dose of these products has been limited by their anticoagulant activity. M402, which is derived from unfractionated heparin, has been engineered to have significantly reduced anticoagulant activity while preserving the relevant antitumor properties of heparin.
Researchers have conducted a series of experiments using different pancreatic cancer models to test the hypothesis that M402 can modulate tumor progression and metastasis and enhance the efficacy of gemcitabine, a first-line standard of care chemotherapy treatment for pancreatic cancer. The preclinical results showed that M402 in combination with gemcitabine prolonged survival and substantially lowered the incidence of metastasis.
View posters related to numerous preclinical studies.
Momenta initiated a Phase 1/2 clinical trial with M402 in 2012.
Last revised 7/2/2012